$OMER
OMEROS CORP Stock $omer

$omer Overview Financials Valuation SEC Filings Company Website

2017 Q3 Form 10-Q Financial Statement

#000128581917000011 Filed on August 08, 2017

Income Statement

Concept	2017 Q3	2017 Q2	2016 Q2
Revenue	$21.66M	$17.15M	$10.00M
YoY Change	91.85%	71.44%	213.9%
Cost Of Revenue	$184.0K	$157.0K	$327.0K
YoY Change	-51.32%	-51.99%	-10.41%
Gross Profit	$21.47M	$16.99M	$9.677M
YoY Change	96.81%	75.61%	242.91%
Gross Profit Margin	99.15%	99.08%	96.73%
Selling, General & Admin	$11.75M	$15.80M	$10.38M
YoY Change	12.33%	52.22%	31.56%
% of Gross Profit	54.72%	92.97%	107.26%
Research & Development	$14.84M	$13.14M	$10.23M
YoY Change	18.76%	28.4%	-6.14%
% of Gross Profit	69.08%	77.3%	105.72%
Depreciation & Amortization	$150.0K	$110.0K	$70.00K
YoY Change	66.67%	57.14%	40.0%
% of Gross Profit	0.7%	0.65%	0.72%
Operating Expenses	$26.77M	$29.09M	$20.93M
YoY Change	14.75%	38.97%	9.29%
Operating Profit	-$5.110M	-$11.94M	-$10.93M
YoY Change	-57.55%	9.24%	-31.55%
Interest Expense	$2.780M	$2.723M	$1.857M
YoY Change	30.21%	46.63%	98.19%
% of Operating Profit
Other Income/Expense, Net	$408.0K	$303.0K	$174.0K
YoY Change	93.36%	74.14%	-22.32%
Pretax Income	-$7.480M	-$14.36M	-$12.61M
YoY Change	-46.42%	13.88%	-24.4%
Income Tax
% Of Pretax Income
Net Earnings	-$7.482M	-$14.36M	-$12.61M
YoY Change	-46.41%	13.85%	-24.39%
Net Earnings / Revenue	-34.55%	-83.72%	-126.07%
Basic Earnings Per Share
Diluted Earnings Per Share	-$161.7K	-$326.1K	-$321.8K
COMMON SHARES
Basic Shares Outstanding	44.80M shares	43.94M shares	39.14M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2017 Q3	2017 Q2	2016 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$86.80M	$29.70M	$21.20M
YoY Change	83.12%	40.09%	-58.75%
Cash & Equivalents	$1.026M	$3.386M	$4.589M
Short-Term Investments	$85.80M	$26.30M	$16.60M
Other Short-Term Assets	$5.700M	$3.400M	$2.300M
YoY Change	307.14%	47.83%	2029.63%
Inventory	$822.0K	$905.0K	$1.780M
Prepaid Expenses	$5.691M	$3.446M	$2.282M
Receivables	$24.60M	$19.10M	$8.800M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$117.9M	$53.09M	$34.11M
YoY Change	94.39%	55.68%	-39.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.785M	$1.426M	$1.251M
YoY Change	48.01%	13.99%	58.56%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$5.800M	$5.800M	$73.00K
YoY Change	7845.21%	7845.21%	-85.04%
Total Long-Term Assets	$7.620M	$7.261M	$12.00M
YoY Change	-37.1%	-39.51%	513.65%
TOTAL ASSETS
Total Short-Term Assets	$117.9M	$53.09M	$34.11M
Total Long-Term Assets	$7.620M	$7.261M	$12.00M
Total Assets	$125.5M	$60.35M	$46.11M
YoY Change	72.5%	30.9%	-21.37%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$3.680M	$2.572M	$5.420M
YoY Change	-7.65%	-52.55%	33.99%
Accrued Expenses	$20.26M	$21.64M	$10.45M
YoY Change	70.52%	107.07%	54.68%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$368.0K	$250.0K	$193.0K
YoY Change	93.68%	29.53%	-97.92%
Total Short-Term Liabilities	$24.69M	$24.75M	$16.07M
YoY Change	53.76%	54.08%	-20.06%
LONG-TERM LIABILITIES
Long-Term Debt	$82.78M	$81.51M	$69.83M
YoY Change	17.77%	16.72%	225.15%
Other Long-Term Liabilities	$8.800M	$8.900M	$9.200M
YoY Change	-4.35%	-3.26%	1.1%
Total Long-Term Liabilities	$82.78M	$81.51M	$69.83M
YoY Change	17.77%	16.72%	225.15%
TOTAL LIABILITIES
Total Short-Term Liabilities	$24.69M	$24.75M	$16.07M
Total Long-Term Liabilities	$82.78M	$81.51M	$69.83M
Total Liabilities	$107.5M	$106.3M	$85.90M
YoY Change	24.46%	23.71%	106.62%
SHAREHOLDERS EQUITY
Retained Earnings	-$506.8M	-$499.3M	-$436.3M
YoY Change	12.56%	14.45%	20.06%
Common Stock	$480.0K	$444.0K	$393.0K
YoY Change	11.89%	12.98%	3.69%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$9.211M	-$54.85M	-$49.00M
YoY Change
Total Liabilities & Shareholders Equity	$125.5M	$60.35M	$46.11M
YoY Change	72.5%	30.9%	-21.37%

Cashflow Statement

Concept	2017 Q3	2017 Q2	2016 Q2
OPERATING ACTIVITIES
Net Income	-$7.482M	-$14.36M	-$12.61M
YoY Change	-46.41%	13.85%	-24.39%
Depreciation, Depletion And Amortization	$150.0K	$110.0K	$70.00K
YoY Change	66.67%	57.14%	40.0%
Cash From Operating Activities	-$11.20M	-$8.160M	-$12.79M
YoY Change	-0.18%	-36.2%	-22.67%
INVESTING ACTIVITIES
Capital Expenditures	-$30.00K	-$250.0K	-$30.00K
YoY Change	-40.0%	733.33%	-72.73%
Acquisitions
YoY Change
Other Investing Activities	-$59.51M	$6.090M	-$4.380M
YoY Change	190.29%	-239.04%	-122.19%
Cash From Investing Activities	-$59.54M	$5.850M	-$4.410M
YoY Change	189.87%	-232.65%	-122.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$63.60M
YoY Change	70.51%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	68.38M	4.410M	20.82M
YoY Change	82.49%	-78.82%	-1167.69%
NET CHANGE
Cash From Operating Activities	-11.20M	-8.160M	-12.79M
Cash From Investing Activities	-59.54M	5.850M	-4.410M
Cash From Financing Activities	68.38M	4.410M	20.82M
Net Change In Cash	-2.360M	2.100M	3.620M
YoY Change	-141.33%	-41.99%	220.35%
FREE CASH FLOW
Cash From Operating Activities	-$11.20M	-$8.160M	-$12.79M
Capital Expenditures	-$30.00K	-$250.0K	-$30.00K
Free Cash Flow	-$11.17M	-$7.910M	-$12.76M
YoY Change	0.0%	-38.01%	-22.34%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2017
	dei	Document Period End Date DocumentPeriodEndDate	2017-06-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0001285819
CY2017Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	44803848	shares
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	OMEROS CORP
	dei	Trading Symbol TradingSymbol	OMER
CY2016Q4	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	1167000	USD
CY2017Q2	omer	Accrued Clinical Trial Costs AccruedClinicalTrialCosts	964000	USD
CY2016Q4	omer	Accrued Contract Research Costs AccruedContractResearchCosts	3030000	USD
CY2017Q2	omer	Accrued Contract Research Costs AccruedContractResearchCosts	4541000	USD
	omer	Long Term Purchase Commitment Termination Fee LongTermPurchaseCommitmentTerminationFee	3700000	USD
CY2017Q2	omer	Loss Contingency Patents Expired Number LossContingencyPatentsExpiredNumber	6	patent
	omer	Noncash Transaction Conversion Of Accrued Interest Into Notes Payable NoncashTransactionConversionOfAccruedInterestIntoNotesPayable	0	USD
	omer	Noncash Transaction Conversion Of Accrued Interest Into Notes Payable NoncashTransactionConversionOfAccruedInterestIntoNotesPayable	1628000	USD
	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	1877000	USD
	omer	Proceedsfrom Stock Optionsand Warrants Exercised ProceedsfromStockOptionsandWarrantsExercised	5637000	USD
	omer	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	1171775	shares
	omer	Stock Issued During Period Shares Stock Optionsand Warrants Exercised StockIssuedDuringPeriodSharesStockOptionsandWarrantsExercised	628470	shares
CY2016Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2519000	USD
CY2017Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	2572000	USD
CY2016Q4	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	1335000	USD
CY2017Q2	us-gaap	Accrued Exchange Fee Rebate Current AccruedExchangeFeeRebateCurrent	3767000	USD
CY2016Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	13252000	USD
CY2017Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	21643000	USD
CY2016Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	2223000	USD
CY2017Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	4484000	USD
CY2016Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	432002000	USD
CY2017Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	444041000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	9602420	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	10435332	shares
CY2016Q4	us-gaap	Assets Assets	67278000	USD
CY2017Q2	us-gaap	Assets Assets	60354000	USD
CY2016Q4	us-gaap	Assets Current AssetsCurrent	60262000	USD
CY2017Q2	us-gaap	Assets Current AssetsCurrent	53093000	USD
CY2016Q4	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	43107000	USD
CY2017Q2	us-gaap	Available For Sale Securities Equity Securities Current AvailableForSaleSecuritiesEquitySecuritiesCurrent	26281000	USD
CY2016Q4	us-gaap	Capital Lease Obligations CapitalLeaseObligations	522000	USD
CY2017Q2	us-gaap	Capital Lease Obligations CapitalLeaseObligations	561000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	758000	USD
	us-gaap	Capital Lease Obligations Incurred CapitalLeaseObligationsIncurred	0	USD
CY2016Q4	us-gaap	Cash Cash	2200000	USD
CY2017Q2	us-gaap	Cash Cash	3400000	USD
CY2015Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1365000	USD
CY2016Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	4589000	USD
CY2016Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2224000	USD
CY2017Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	3386000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	3224000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	1162000	USD
CY2017Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	29700000	USD
CY2016Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q2	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2016Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2017Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	150000000	shares
CY2016Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43819133	shares
CY2017Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	44447603	shares
CY2016Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43819133	shares
CY2017Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	44447603	shares
CY2016Q4	us-gaap	Common Stock Value CommonStockValue	438000	USD
CY2017Q2	us-gaap	Common Stock Value CommonStockValue	444000	USD
CY2016Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12612000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-33151000	USD
CY2017Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-14359000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-29448000	USD
CY2016Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	327000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	654000	USD
CY2017Q2	us-gaap	Cost Of Goods Sold CostOfGoodsSold	157000	USD
	us-gaap	Cost Of Goods Sold CostOfGoodsSold	429000	USD
CY2016Q4	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	85063000	USD
CY2017Q2	us-gaap	Debt And Capital Lease Obligations DebtAndCapitalLeaseObligations	86811000	USD
CY2016Q4	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	3958000	USD
CY2017Q2	us-gaap	Debt Instrument Unamortized Discount Premium Net DebtInstrumentUnamortizedDiscountPremiumNet	3755000	USD
CY2016Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1395000	USD
CY2017Q2	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	1295000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	102000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Current DeferredRentCreditCurrent	288000	USD
CY2016Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	9142000	USD
CY2017Q2	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	8940000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	122000	USD
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	234000	USD
CY2016Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.32
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.86
CY2017Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.33
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.67
CY2016Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	4551000	USD
CY2017Q2	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	5147000	USD
CY2017Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	22700000	USD
CY2016Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10375000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	21485000	USD
CY2017Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	15796000	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	28267000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-270000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	8428000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1308000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-223000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	242000	USD
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1680000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent		USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent		USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2289000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	7038000	USD
CY2016Q4	us-gaap	Inventory Net InventoryNet	1128000	USD
CY2017Q2	us-gaap	Inventory Net InventoryNet	905000	USD
CY2016Q4	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	101000	USD
CY2017Q2	us-gaap	Inventory Raw Materials Net Of Reserves InventoryRawMaterialsNetOfReserves	101000	USD
CY2016Q4	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	854000	USD
CY2017Q2	us-gaap	Inventory Work In Process Net Of Reserves InventoryWorkInProcessNetOfReserves	537000	USD
CY2016Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	67278000	USD
CY2016Q2	us-gaap	Interest Expense InterestExpense	1857000	USD
	us-gaap	Interest Expense InterestExpense	3232000	USD
CY2017Q2	us-gaap	Interest Expense InterestExpense	2723000	USD
	us-gaap	Interest Expense InterestExpense	5386000	USD
	us-gaap	Interest Paid InterestPaid	2005000	USD
	us-gaap	Interest Paid InterestPaid	3372000	USD
CY2016Q4	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	173000	USD
CY2017Q2	us-gaap	Inventory Finished Goods Net Of Reserves InventoryFinishedGoodsNetOfReserves	267000	USD
CY2017Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60354000	USD
CY2016Q4	us-gaap	Liabilities Current LiabilitiesCurrent	16071000	USD
CY2017Q2	us-gaap	Liabilities Current LiabilitiesCurrent	24753000	USD
CY2016Q4	us-gaap	Loans Payable LoansPayable	4025000	USD
CY2017Q2	us-gaap	Loans Payable LoansPayable	4107000	USD
CY2016Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	198000	USD
CY2017Q2	us-gaap	Long Term Debt Current LongTermDebtCurrent	250000	USD
CY2016Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	79512000	USD
CY2017Q2	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	81511000	USD
CY2016	us-gaap	Loss Contingency Patents Allegedly Infringed Number LossContingencyPatentsAllegedlyInfringedNumber	3	patent
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	22431000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	5513000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	10216000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	16510000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29423000	USD
CY2016	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	51500000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20900000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-20861000	USD
CY2016Q2	us-gaap	Net Income Loss NetIncomeLoss	-12612000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-33151000	USD
CY2016	us-gaap	Net Income Loss NetIncomeLoss	-66700000	USD
CY2017Q2	us-gaap	Net Income Loss NetIncomeLoss	-14359000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29400000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-29448000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	388000	USD
	us-gaap	Noncash Or Part Noncash Acquisition Value Of Assets Acquired1 NoncashOrPartNoncashAcquisitionValueOfAssetsAcquired1	163000	USD
CY2016Q4	us-gaap	Notes Payable NotesPayable	80516000	USD
CY2017Q2	us-gaap	Notes Payable NotesPayable	82143000	USD
CY2016	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2016Q2	us-gaap	Operating Expenses OperatingExpenses	20933000	USD
CY2017Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2016Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	946000	USD
	us-gaap	Operating Expenses OperatingExpenses	47804000	USD
CY2017Q2	us-gaap	Operating Expenses OperatingExpenses	29090000	USD
	us-gaap	Operating Expenses OperatingExpenses	54073000	USD
CY2016Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10929000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30381000	USD
CY2017Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-11939000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-24665000	USD
CY2017Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	2740000	USD
CY2016Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	174000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	462000	USD
CY2017Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	303000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	603000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	684000	USD
	us-gaap	Paid In Kind Interest PaidInKindInterest	2012000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	20625000	USD
	us-gaap	Payments To Acquire Available For Sale Securities PaymentsToAcquireAvailableForSaleSecurities	1102000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	34000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	316000	USD
CY2016Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2017Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2016Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2017Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2016Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2017Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2016Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2017Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2016Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	1766000	USD
CY2017Q2	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	3446000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	724000	USD
	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	19864000	USD
	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	30875000	USD
	us-gaap	Proceeds From Sale Of Available For Sale Securities ProceedsFromSaleOfAvailableForSaleSecurities	17928000	USD
CY2016Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1181000	USD
CY2017Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1426000	USD
CY2016Q4	us-gaap	Receivables Net Current ReceivablesNetCurrent	12037000	USD
CY2017Q2	us-gaap	Receivables Net Current ReceivablesNetCurrent	19075000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	34000	USD
	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	124000	USD
CY2016Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10231000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25665000	USD
CY2017Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	13137000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	25377000	USD
CY2016Q4	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5835000	USD
CY2017Q2	us-gaap	Restricted Cash And Cash Equivalents Noncurrent RestrictedCashAndCashEquivalentsNoncurrent	5835000	USD
CY2016Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-469887000	USD
CY2017Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-499335000	USD
CY2016Q2	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	173000	USD
CY2017Q2	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2016Q2	us-gaap	Revenues Revenues	10004000	USD
	us-gaap	Revenues Revenues	17423000	USD
CY2017Q2	us-gaap	Revenues Revenues	17151000	USD
	us-gaap	Revenues Revenues	29408000	USD
CY2016Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	10004000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	17250000	USD
CY2017Q2	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	17151000	USD
	us-gaap	Sales Revenue Goods Net SalesRevenueGoodsNet	29408000	USD
CY2016Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2610000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	7031000	USD
CY2017Q2	us-gaap	Share Based Compensation ShareBasedCompensation	3132000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	6408000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	3712515	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	6830249	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	9.18
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	514364	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	10.80
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	1668190	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	128131000	USD
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	9809374	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10334730	shares
CY2016Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9.66
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	10.07
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	124321000	USD
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	9972946	shares
CY2017Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice	10.00
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	8.97
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	12.37
CY2017Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	90716000	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P5Y9M7D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y10M27D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P6Y9M29D
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	628470	shares
CY2016Q4	us-gaap	Stockholders Equity StockholdersEquity	-37447000	USD
CY2017Q2	us-gaap	Stockholders Equity StockholdersEquity	-54850000	USD
CY2016	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
	us-gaap	Unrealized Gain Loss On Investments UnrealizedGainLossOnInvestments	0	USD
CY2016Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39178547	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	38747816	shares
CY2017Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	44037471	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	43933022	shares
	us-gaap	Revenue Recognition Sales Of Goods RevenueRecognitionSalesOfGoods	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Product Sales, Net</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">We record revenue from product sales when the product is delivered to our wholesalers. Product sales to a wholesaler are not recorded if we determine that the wholesaler’s on-hand OMIDRIA inventory, based on sell-through and inventory information we regularly receive from our wholesalers, exceeds approximately eight weeks of projected demand.</font></div><div style="line-height:120%;padding-top:12px;text-align:left;text-indent:29px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Product sales are recorded net of wholesaler distribution fees and estimated chargebacks, product returns, rebates and purchase volume discounts. Accruals or allowances are established for these deductions in the same period when revenue is recognized, and actual amounts incurred are offset against the applicable accruals or allowances. We reflect each of these accruals or allowances as either a reduction in the related account receivable or as an accrued liability, depending on how the amount is expected to be settled.</font></div></div>
	us-gaap	Use Of Estimates UseOfEstimates	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;padding-top:12px;text-indent:16px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Use of Estimates</font></div><div style="line-height:120%;padding-bottom:13px;padding-top:12px;text-align:left;text-indent:30px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Significant items subject to such estimates include revenue recognition, fair market value of investments, stock-based compensation expense and accruals for clinical trials and contingencies. We base our estimates on historical experience and on various other factors that we believe are reasonable under the circumstances; however, actual results could differ from these estimates.</font></div></div>

Files In Submission

Name	View Source	Status
0001285819-17-000011-index-headers.html	Edgar Link	pending
0001285819-17-000011-index.html	Edgar Link	pending
0001285819-17-000011.txt	Edgar Link	pending
0001285819-17-000011-xbrl.zip	Edgar Link	pending
ex103_20170603-1.htm	Edgar Link	pending
ex121_20170630.htm	Edgar Link	pending
ex311_20170630.htm	Edgar Link	pending
ex312_20170630.htm	Edgar Link	pending
ex321_20170630.htm	Edgar Link	pending
ex322_20170630.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
omer-20170630.xml	Edgar Link	completed
omer-20170630.xsd	Edgar Link	pending
omer-20170630x10q.htm	Edgar Link	pending
omer-20170630_cal.xml	Edgar Link	unprocessable
omer-20170630_def.xml	Edgar Link	unprocessable
omer-20170630_lab.xml	Edgar Link	unprocessable
omer-20170630_pre.xml	Edgar Link	unprocessable
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$OMER
OMEROS CORP Stock $omer

2017 Q3 Form 10-Q Financial Statement

#000128581917000011 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER OMEROS CORP Stock $omer

2017 Q3 Form 10-Q Financial Statement

#000128581917000011 Filed on August 08, 2017

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$OMER
OMEROS CORP Stock $omer